PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 68
- Registration Number
- NCT00151476
- Locations
- ๐ช๐ธ
Pfizer Investigational Site, Barcelona, Spain
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00151437
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Montreal, Quebec, Canada
A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 625
- Registration Number
- NCT00150241
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Morgantown, West Virginia, United States
12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00150228
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Madison, Wisconsin, United States
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2006-12-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 276
- Registration Number
- NCT00150436
A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 112
- Registration Number
- NCT00150397
- Locations
- ๐ฎ๐ณ
Pfizer Investigational Site, Noida, Uttar Pradesh, India
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 625
- Registration Number
- NCT00150254
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Houston, Texas, United States
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT00150202
- Locations
- ๐ฏ๐ต
Pfizer Investigational Site, Kyoto, Japan
To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 384
- Registration Number
- NCT00150423
A First In Human Study Of PF-00184562 In Healthy Volunteers
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00150215
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Austin, Texas, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath